// App-Quantinova.ai

125 : IMPAIRED ENDOGENOUS THROMBOLYSIS- A NOVEL, POINT-OF-CARE BIOMARKER PREDICTIVE OF ADVERSE CARDIOVASCULAR EVENTS

Researchers

Presenter

  • Diana A Gorog

Principal Investigators

  • N/A

Medical Centers

  • Imperial College, London, University of Hertfordshire, East & North Hertfordshire NHS Trust, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Acute Coronary Syndromes

  • Microvascular complications of diabetes 1

  • End stage renal disease

  • Renal disease

  • Venous thrombosis

Biomarkers

  • Plasminogen activator ihnibitor-1

  • Thrombin-activatable fibrinolysis inhibitor

Drug/Treatment

  • Evithrom

  • Aspirin

  • Albyl-E

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved